T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Intercontinental Exchange
ICE
$84.7B
| $2B | 0.41% |
42,946,920
+3,568,970
| +9% | +$161M |
|
52
EQT Corp
EQT
$33.7B
| $1.98B | 0.41% |
43,922,505
-82,586
| -0.2% | -$3.5M |
|
|
PXD
53
DELISTED
Pioneer Natural Resource Co.
PXD
| $1.94B | 0.4% |
11,849,054
-3,117,336
| -21% | -$479M |
|
54
FirstEnergy
FE
$27B
| $1.94B | 0.4% |
55,250,831
+16,873,365
| +44% | +$631M |
|
55
Johnson & Johnson
JNJ
$626B
| $1.91B | 0.39% |
18,957,383
-599,335
| -3% | -$60.9M |
|
56
CVS Health
CVS
$120B
| $1.9B | 0.39% |
18,388,714
-499,374
| -3% | -$50.5M |
|
|
BNY
57
Bank of New York Mellon
BNY
$111B
| $1.88B | 0.39% |
46,631,026
+28,323,077
| +155% | +$1.1B |
|
58
Wynn Resorts
WYNN
$10.8B
| $1.83B | 0.38% |
14,576,801
-2,470,893
| -14% | -$353M |
|
|
59
Elevance Health
ELV
$85.4B
| $1.79B | 0.37% |
11,566,057
+6,343,303
| +121% | +$903M |
|
60
Home Depot
HD
$343B
| $1.78B | 0.37% |
15,665,799
-933,338
| -6% | -$103M |
|
61
Vulcan Materials
VMC
$36.6B
| $1.78B | 0.37% |
21,063,719
-70,149
| -0.3% | -$5.42M |
|
62
Regeneron Pharmaceuticals
REGN
$81.8B
| $1.75B | 0.36% |
3,876,501
-63,353
| -2% | -$26.8M |
|
63
Humana
HUM
$45.8B
| $1.75B | 0.36% |
9,805,001
+621,347
| +7% | +$98.3M |
|
|
HBI
64
DELISTED
Hanesbrands
HBI
| $1.74B | 0.36% |
51,806,771
+3,242,255
| +7% | +$98.3M |
|
65
O'Reilly Automotive
ORLY
$74.5B
| $1.73B | 0.36% |
119,936,790
-4,951,065
| -4% | -$66.5M |
|
|
HSP
66
DELISTED
HOSPIRA INC
HSP
| $1.71B | 0.35% |
19,507,117
-1,934,926
| -9% | -$152M |
|
67
Textron
TXT
$15B
| $1.66B | 0.34% |
37,409,514
+4,061,776
| +12% | +$177M |
|
|
LNKD
68
DELISTED
LinkedIn Corporation
LNKD
| $1.65B | 0.34% |
6,612,348
-349,475
| -5% | -$86.8M |
|
69
PepsiCo
PEP
$187B
| $1.63B | 0.34% |
17,019,451
-1,152,027
| -6% | -$111M |
|
70
Becton Dickinson
BDX
$48.9B
| $1.62B | 0.33% |
11,574,568
+1,646,862
| +17% | +$231M |
|
71
Vertex Pharmaceuticals
VRTX
$134B
| $1.59B | 0.33% |
13,516,888
+226,285
| +2% | +$27.1M |
|
72
United Airlines
UAL
$40.5B
| $1.58B | 0.33% |
23,506,451
+886,676
| +4% | +$60.1M |
|
73
RTX Corp
RTX
$297B
| $1.55B | 0.32% |
20,985,967
-4,684,922
| -18% | -$350M |
|
74
Tesla
TSLA
$1.28T
| $1.53B | 0.32% |
121,893,165
+32,044,020
| +36% | +$433M |
|
|
75
Medtronic
MDT
$115B
| $1.53B | 0.32% |
19,615,336
+11,453,179
| +140% | +$868M |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.